LifeMD Inc
$ 3.56
4.71%
07 Aug - close price
- Market Cap 171,595,000 USD
- Current Price $ 3.56
- High / Low $ 3.64 / 3.36
- Stock P/E N/A
- Book Value 0.32
- EPS -0.56
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.19 %
- ROE -5.16 %
- 52 Week High 7.32
- 52 Week Low 2.56
About
LifeMD, Inc. is a direct-to-patient telehealth company connecting consumers with healthcare professionals for care in various indications, including concierge care, men's sexual health, dermatology, and others in the United States. . The company is headquartered in New York, New York.
Analyst Target Price
$8.62
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-05 | 2026-05-06 | 2026-03-09 | 2025-11-17 | 2025-08-04 | 2025-05-06 | 2025-03-10 | 2024-11-07 | 2024-08-07 | 2024-05-08 | 2024-03-11 | 2023-11-08 |
| Reported EPS | -0.16 | -0.1516 | 0.06 | -0.08 | -0.01 | 0.03 | 0.21 | 0.09 | 0.06 | 0.01 | -0.12 | 0.08 |
| Estimated EPS | -0.2 | -0.1167 | 0.09 | 0.05 | 0.18 | 0.14 | 0.14 | 0.07 | 0.04 | -0.01 | -0.14 | 0.03 |
| Surprise | 0.04 | -0.0349 | -0.03 | -0.13 | -0.19 | -0.11 | 0.07 | 0.02 | 0.02 | 0.02 | 0.02 | 0.05 |
| Surprise Percentage | 20% | -29.9057% | -33.3333% | -260% | -105.5556% | -78.5714% | 50% | 28.5714% | 50% | 200% | 14.2857% | 166.6667% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: LFMD
2026-08-07 13:41:35
HC Wainwright has lowered its price target for LifeMD (NASDAQ:LFMD) to $9.00 from $10.00 but maintained a "buy" rating, indicating a potential upside of 164.71%. The revision follows LifeMD's recent quarterly results, which missed analyst expectations with a reported loss of $0.16 per share and revenue of $47.28 million. Despite mixed analyst sentiment, with a consensus "Moderate Buy" rating, institutional investors have shown increased interest in the company.
2026-08-07 05:35:10
LifeMD, Inc.'s average 12-month price target has been reduced from $9.88 to $9 by 8 analysts, with forecasts ranging from $7 to $15 per share. Despite the cut, this new target still suggests a substantial 145% potential upside from its Aug. 5 closing price. The consensus rating for LFMD remains a "Buy" from all covering analysts.
2026-08-06 09:56:00
This article provides an AI-driven analysis of LifeMD Inc. 8.875% Series A Cumulative Perpetual Preferred Stock (NASDAQ: LFMDP), noting a neutral sentiment and a wait-and-see approach. It highlights an exceptional 12.0:1 risk-reward setup targeting a 3.6% gain, with specific trading strategies for position trading, momentum breakout, and risk hedging. The analysis also includes multi-timeframe signal analysis and real-time trading signals for subscribers.
2026-08-06 05:41:17
LifeMD (NASDAQ:LFMD) reported its quarterly earnings, missing analyst expectations with an adjusted EPS of negative $0.16 against a consensus of negative $0.15, and revenue of $47.28 million, falling short of the $49.16 million estimate. The telehealth company also reduced its full-year 2026 guidance due to elevated customer acquisition costs and a $39 weight-management promotion, but anticipates adjusted EBITDA profitability in Q3 driven by improved underlying economics and growth initiatives. The stock traded down $0.22 following the announcement.
2026-08-06 05:41:10
LifeMD reported Q2 2026 telehealth revenue of $47.3 million, a 4% year-over-year decrease, though within guidance, as it transitions weight-management patients to branded GLP-1 therapies and longer subscriptions. The company increased active subscribers by 20% to approximately 356,000, and gross margin expanded to 89%. However, GAAP net loss widened to $7.9 million, and adjusted EBITDA shifted to a loss of $3.5 million, leading to a reduced full-year 2026 revenue guidance of $205.5–$212.5 million and adjusted EBITDA guidance of -$6.0 million to breakeven.
2026-08-06 05:41:10
LifeMD (NASDAQ:LFMD) reported disappointing Q2 2026 results, missing both revenue and non-GAAP EPS consensus estimates. The virtual care and pharmacy services company posted revenue of $47.3 million against a $50.1 million consensus, and a non-GAAP loss per share of $0.16 compared to an expected $0.15 loss. Shares reacted negatively, dropping approximately 10.9% in extended trading, adding to a recent difficult period for the stock.
